The Quercus genus provides a large amount of biomaterial with many applications in fields like pharmaceutics, cosmetics, and foodstuff areas. Due to the worldwide dissemination of the genus, many species were used for centuries in traditional healing methods or in the wine maturing process. This review aims to bring together the results about phytoconstituents from oak extracts and their biological applicability as antioxidants, antimicrobial, anticancer, etc. The literature data used in this paper were collected via PubMed, Scopus, and Science Direct (2010–June 2020). The inclusion criteria were papers published in English, with information about phytoconstituents from Quercus species (leaves, bark and seeds/acorns) and biological activities such as antioxidant, antibacterial, antiobesity, anti-acne vulgaris, antifungal, anticancer, antiviral, antileishmanial, antidiabetic, anti-inflammatory. The exclusion criteria were the research of other parts of the Quercus species (e.g., galls, wood, and twigs); lack of information about phytochemistry and biological activities; non-existent Quercus species reported by the authors. The most studied Quercus species, in terms of identified biomolecules and biological activity, are Q. brantii, Q. infectoria and Q. robur. The Quercus species have been reported to contain several phytoconstituents. The main bioactive phytochemicals are phenolic compounds, volatile organic compounds, sterols, aliphatic alcohols and fatty acids. The, Quercus species are intensely studied due to their antioxidant, anti-inflammatory, antimicrobial, and anticancer activities, provided by their phytochemical composition. The general conclusion is that oak extracts can be exploited for their biological activity and can be used in research fields, such as pharmaceutical, nutraceutical and medical.

Nanoparticles are intensely studied because of their importance in diverse fields of biotechnology, especially in medicine. This paper highlights that waste bark can be a cheap source of biocompounds, with high recovery and functionalization potential in nanoparticle synthesis. Due to their biocompatibility and activity as antioxidant, antimicrobial, and anticancer agents, the green synthesis of metallic nanoparticles is of great importance. This review aims to bring together the diversity of synthesized metallic nanoparticles mediated by bark extracts obtained from different woody vascular plants, the phytoconstituents responsible for the reduction of metal salts, and the activity of metallic nanoparticles as diverse agents in combating the microbial, oxidant, and cancer activity. The literature data highlight the fact that metallic nanoparticles obtained from natural compounds are proven reducing agents with multiple activities. Thus, the activity of natural components in environmental protection and human health is confirmed.

Cell biology, plant-based extracts, structural chemistry, and laboratory in vitro or in vivo experiments are the principal aspects or interfaces that can contribute to discovering new possibilities in cancer therapy and to developing improved chemotherapeutics. Forestry residues can be used for their wealthy resource in polyphenols and other phytoconstituents known for anticancer properties. This review is designed to bring together information on the in vitro or in vivo anticancer potential of woody vascular plants especially the bark extracts (BE) and biosynthesized metallic nanoparticles (BMN) using bark extracts. Type of extracts, main phytoconstituents found in extracts responsible for the anticancer activity, and targeted cancerous cell lines were followed. The literature data were collected via Clarivate Analytics, Science Direct, PubMed, and Google Academic (2011–2021). The search terms were: bark extracts, metallic nanoparticles, silver nanoparticles, gold nanoparticles, anticancer, cytotoxic activity, antiproliferative effect, and antimetastatic potential in vitro and in vivo. All of the search terms listed above were used in different combinations. The literature data highlight the efficaciousness of the BE and BMN as anticancer agents in in vitro experiments and showed the mechanism of action and their advantage of nontoxicity on normal cells. In vitro testing has shown promising results of the BE and BMN effect on different cancer cell lines. In vivo testing is lacking and more data is necessary for drug development on animal models.

Background: Pediatric obesity (PO) is a chronic disease requiring multidisciplinary management. Recent clinical guidelines emphasize the need for accessible, patient-centered solutions, positioning mHealth interventions as vital “clinical extenders” in modern practice. Objective: This systematic review and meta-analysis evaluate the efficacy and evolution of mHealth interventions for PO management between 2020 and 2026. Methods: A systematic search of electronic databases identified randomized controlled trials (RCTs) investigating mHealth for PO. Quality was assessed using the Cochrane RoB 2 tool, and a meta-analysis was performed on a subset of studies reporting zBMI data. Results: Twenty-three RCTs met the inclusion criteria, of which six were included in the quantitative synthesis. The meta-analysis demonstrated a statistically significant reduction in BMI z-score (MD = −0.20; 95% CI: −0.36 to −0.04; p = 0.02), with moderate heterogeneity (I² = 60%; Q = 13.5, p = 0.019). Beyond anthropometric outcomes, mHealth interventions consistently improved behavioral parameters, including dietary quality and sedentary time. However, engagement declined over time in standalone digital interventions (“mHealth fade-out”), whereas hybrid models integrating human support demonstrated improved retention and sustained effects. Anthropometric and behavioral outcomes showed partially divergent trajectories, with behavioral improvements often preceding measurable changes in BMI, and data on body composition were rarely reported, limiting a more precise understanding of changes in adiposity beyond BMI. Conclusions: mHealth is an effective catalyst for obesity management when integrated into a multidisciplinary framework. Future protocols must prioritize developmental tailoring—targeting parental empowerment in early childhood and encouraging adolescent autonomy—to ensure sustained engagement and a clinical focus that looks beyond BMI.